RPC Pharma Ltd Amends Akari Therapeutics Stake

TL;DR

RPC Pharma Ltd filed an amendment for Akari Therapeutics (AKTX) - ownership change, details TBD.

AI Summary

On June 20, 2024, RPC Pharma Ltd, acting as trustee for the Sonic Healthcare Holding Co, filed an amendment (Amendment No. 8) to its Schedule 13D for Akari Therapeutics Plc. This filing indicates a change in beneficial ownership, though specific new holdings or changes in percentage are not detailed in the provided text.

Why It Matters

Changes in beneficial ownership filings like this can signal shifts in major investor positions, potentially impacting stock price and corporate strategy.

Risk Assessment

Risk Level: medium — Schedule 13D filings indicate significant ownership changes, which can introduce volatility and uncertainty.

Key Players & Entities

• RPC Pharma Ltd (company) — Filing entity
• Akari Therapeutics Plc (company) — Subject company
• Sonic Healthcare Holding Co (company) — Beneficial owner group
• Jennifer L. Porte (person) — Mentioned in filing header

FAQ

Key Financial Figures

• $0.0001 — c (Name of Issuer) Ordinary Shares, $0.0001 par value (Title of Class of Securiti
• $1.885 — ary Shares) at a combined unit price of $1.885 per ADS (comprised of $1.76 per ADS and
• $1.76 — t price of $1.885 per ADS (comprised of $1.76 per ADS and $0.125 per warrant). The fu
• $0.125 — per ADS (comprised of $1.76 per ADS and $0.125 per warrant). The funds used by Dr. Pru

Filing Documents

• tm2417623d1_sc13da.htm (SC 13D/A) — 55KB
• 0001104659-24-073133.txt ( ) — 57KB

Source and Amount of Funds or Other Consideration

Item 3. Source and Amount of Funds or Other Consideration.

of the Prior Schedule

Item 3 of the Prior Schedule 13D is hereby supplemented by adding the following paragraph: On May 31, 2024, the Issuer closed a private placement of the Issuer’s securities (the “May 2024 PIPE”), pursuant to which, Dr. Prudo purchased 663,129 ADSs (representing 1,326,258,000 Ordinary Shares) and Series C Warrants to purchase 663,129 ADSs (representing 1,326,258,000 Ordinary Shares) at a combined unit price of $1.885 per ADS (comprised of $1.76 per ADS and $0.125 per warrant). The funds used by Dr. Prudo to acquire the ADSs were from his personal funds.

Purpose of Transaction

Item 4. Purpose of Transaction. On May 31, 2024, Dr. Prudo purchased the securities described in the May 2024 Private Placement as described in Item 3 above.

Interest in Securities of the Issuer

Item 5. Interest in Securities of the Issuer. (a) Dr. Prudo, either in his individual capacity or as sole manager and member of RPC and Praxis, respectively, beneficially owns an aggregate of 4,507,314,800 Ordinary Shares (represented by Ordinary Shares or American Depositary Shares), including (i) 3,657,838,600 Ordinary Shares, (ii) options to purchase 10,000,000 Ordinary Shares, (iii) 38,709,600 Ordinary Shares held by Praxis, (iv) 800,766,600 Ordinary Shares held by RPC, which represents approximately 19.2% of the Issuer’s Ordinary Shares (not including RPC’s warrants to purchase 9,210,500 Ordinary Shares). RPC beneficially owns the 800,766,600 Ordinary Shares reported on the third cover page, which represents approximately 3.4% of the Issuer’s Ordinary Shares, and separately, warrants to purchase 9,210,500 Ordinary Shares. Voting and investment decisions with respect to such shares are controlled by Dr. Prudo. Praxis beneficially owns the 38,709,600 Ordinary Shares reported on the fourth cover page, which represents approximately 0.2% of the Issuer’s Ordinary Shares. Voting and investment decisions with respect to such shares are controlled by Dr. Prudo. The percentage of beneficial ownership reported on the Reporting Persons’ cover pages to this Amendment No. 8 is based on (i) 23,482,497,523 Ordinary Shares outstanding as of June 7, 2024 as per information provided to Dr. Prudo by the Issuer. As set forth above, Dr. Prudo’s aggregate beneficial ownership percentage of the Issuer’s Ordinary Shares excludes Warrants to purchase 1,640,159,100 Ordinary Shares. All Warrants held by Dr. Prudo are subject to a 9.99% beneficial ownership limitation. Dr. Prudo disclaims beneficial ownership of the Warrants and securities issuable upon exercise of the Warrants. (b) Reporting Person Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Ray Prudo, M.D. 3,667,838,600 839,476,200 3,667,

Signatures

Signatures After reasonable inquiry and to the best of the undersigned’s knowledge and belief, each of the undersigned hereby certifies that the information set forth in this statement is true, complete and correct. Dated: June 20, 2024 By: /s/ Ray Prudo Ray Prudo, M.D. Dated: June 20, 2024 RPC PHARMA LIMITED By: /s/ Ray Prudo Name: Ray Prudo, M.D. Title: Authorized Person Dated: June 20, 2024 Praxis Trustees Limited As trustee of The Sonic Healthcare Holding Company By: /s/ Jodie Travers Name: Jodie Travers Title: Director for and on behalf of Praxis Trustees Limited By: /s/ Tom Zierer Name: Tom Zierer Title: Director for and on behalf of Praxis Trustees Limited

View Full Filing

View this SC 13D/A filing on SEC EDGAR